TY - JOUR AU - Teh, C.L. AU - Cheong, Y.K. AU - Wan, S.A. AU - Ling, G.R. PY - 2019/10/24 Y2 - 2024/03/29 TI - Treat-to-target (T2T) of serum urate (SUA) in gout: a clinical audit in real-world gout patients JF - Reumatismo JA - Reumatismo VL - 71 IS - 3 SE - Articles DO - 10.4081/reumatismo.2019.1225 UR - https://www.reumatismo.org/reuma/article/view/1225 SP - 154-159 AB - <p>Treat-to-target (T2T) for gout has been established recently to improve its management, which has been reported to be sub-optimal with significant gaps between the goals of treatment and day-to-day clinical practice. T2T recommended a goal of serum urate (SUA) target of &lt;360 μmoI/L in all patients with gout and &lt;300 μmoI/L in patients with tophaceous or severe gout. T2T strategy was applied in the management of gout patients in two Rheumatology clinics from 1 January 2016 onwards. We performed a clinical audit to assess T2T of SUA in gout patients and to identify causes for failure to achieve target SUA among them. There were a total of 304 patients for our analysis. They were of multi-ethnic origin with male predominance (88.8%). They had a mean age of 57.7+13.7 years and mean disease duration of 10.1+8.7 years. The most common comorbidities were hypertension (76.2%), dyslipidemia (52.5%) and diabetes mellitus (DM) (27.4%). Our patients’ body mass indexes showed that 47.7% were obese while 34.2% were overweight. Up to 62.4% of our patients had tophi and 42.6% had joint deformities. Only 34.9% of patients achieved target SUA. Nonadherence (52.3%) was the main reason identified for failure to achieve target SUA. The independent predictors for failure to achieve target SUA were nonadherence (HR=7.84, p=0.000) and presence of tophi (HR=1.95, p=0.001).</p> ER -